// App-Quantinova.ai

Su1472 : Prognosis and Therapy for Ruptured Hepatocellular Carcinoma (HCC): Should NaiVE HCC Rupture BE Included in T4?

Researchers

Presenter

  • Akiko Shiraishi

Principal Investigators

  • Atsushi Hiraoka

  • Hideki Kawasaki

  • Masashi Hirooka

  • Bunzo Matsuura

  • Yoichi Hiasa

  • Kojiro Michitaka

Medical Centers

  • Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shigenobu, Ehime, Japan

  • Department of Surgery, Ehime Prefectural Central Hospital, Matsuyama, Japan

  • Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • Alpha-fetoprotein

  • Human albumin

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved